Table 1 Clinical and pathological data of sporadic Alzheimer’s disease cases, Down syndrome cases, and nondemented control subjects
Aβ4–x (029-2) | Aβ (IC16) | ||||||
|---|---|---|---|---|---|---|---|
Case | Age (years) | Braak stage | ApoE | SP | CAA | SP | CAA |
Sporadic AD cases | |||||||
AD-1 | 87 | V | 3/3 | ++ | ++ | +++ | ++ |
AD-2 | 83 | VI | 4/3 | + | + | +++ | + |
AD-3 | 78 | V | 4/3 | ++ | + | +++ | ++ |
AD-4 | 79 | IV | 4/3 | ++ | +++ | ++ | +++ |
AD-5 | 82 | V | 4/4 | + | + | +++ | ++ |
AD-6 | 84 | IV | 4/3 | ++ | ++ | +++ | +++ |
AD-7 | 85 | VI | 3/3 | (+) | − | +++ | ++ |
AD-8 | 92 | IV | 3/3 | + | + | ++ | + |
AD-9 | 92 | IV | 4/2 | + | ++ | +++ | ++ |
AD-10 | 73 | IV | 4/4 | + | ++ | +++ | +++ |
AD-11 | 92 | IV | 3/3 | ++ | + | +++ | ++ |
AD-12 | 93 | IV | 3/3 | +++ | (+) | +++ | (+) |
AD-13 | 81 | IV | n.d. | ++ | ++ | +++ | +++ |
AD-14 | 95 | IV | 3/3 | + | − | ++ | − |
AD-15 | 91 | IV | 4/3 | + | + | +++ | + |
AD-16 | 65 | VI | 3/3 | (+) | − | ++ | − |
AD-17 | 79 | V | 3/3 | + | + | ++ | + |
Nondemented control cases | |||||||
NDC-1 | 87 | II | n.d. | − | − | − | − |
NDC-2 | 90 | I | 2/2 | + | + | ++ | ++ |
NDC-3 | 79 | II | 4/3 | + | − | ++ | − |
NDC-4 | 89 | III | n.d. | − | + | − | + |
NDC-5 | 78 | I | 3/3 | − | + | (−) | − |
NDC-6 | 82 | I | 3/3 | − | − | − | − |
Down syndrome | |||||||
DS-1 | 64 | V | 3/3 | ++ | ++ | +++ | +++ |
DS-2 | 58 | VI | 4/3 | ++ | +++ | +++ | +++ |